NICE vs ESC: Management of Venous Thromboembolism (2025)
This guide provides a comparative overview of the 2025 National Institute for Health and Care Excellence (NICE) guideline (NG158) and the 2024 European Society of Cardiology (ESC) guideline for the management of venous thromboembolism (VTE). While the ESC guideline offers a broad European perspective, this comparison focuses on its relevance and key points of divergence for clinicians practising within the UK's National Health Service (NHS). The goal is to highlight practical differences in diagnostic pathways, treatment strategies, and management of special situations to inform clinical decision-making.
See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.
Diagnosis and Initial Assessment
Both guidelines emphasise rapid risk-stratification and accurate diagnosis to guide management, but their recommended pathways differ in structure and initial test selection.
NICE Approach (NG158)
- Pulmonary Embolism (PE): For patients with suspected PE, NICE recommends using the two-level PE Wells Score (stratifying patients into "PE likely" or "PE unlikely").
- First-line Imaging: For patients in the "PE likely" category, NICE advises proceeding directly to computed tomography pulmonary angiography (CTPA).
- D-dimer Use: D-dimer testing is reserved only for patients in the "PE unlikely" group. A negative D-dimer excludes PE without the need for imaging.
- Deep Vein Thrombosis (DVT): Similarly, for suspected DVT, NICE uses the two-level DVT Wells Score. Patients in the "DVT likely" category should undergo immediate compression duplex ultrasound (CDUS). D-dimer is used only for the "DVT unlikely" group.
Practical Takeaway: The NICE pathway is binary and highly standardised, minimising imaging in low-risk patients by strictly limiting D-dimer use to this group.
ESC Approach
- Clinical Probability: The ESC also recommends clinical probability assessment (e.g., Wells Score or the Revised Geneva Score) but often uses a three-level stratification (low, intermediate, high).
- D-dimer Application: The ESC advocates for age-adjusted D-dimer thresholds (age × 100 μg/L in patients >50 years) in patients with low or intermediate clinical probability, which increases specificity and reduces unnecessary imaging in older patients.
- Imaging: Imaging (CTPA or CDUS) is recommended for patients with a high clinical probability or a positive D-dimer.
Key Difference: The most significant divergence is the ESC's endorsement of age-adjusted D-dimer, a strategy not explicitly recommended in the 2025 NICE guideline. For UK clinicians, adopting age-adjusted D-dimer could be considered a pragmatic, evidence-based adaptation, especially in older populations, though local trust pathways may vary.
Anticoagulation Treatment
Both guidelines strongly recommend Direct Oral Anticoagulants (DOACs) over vitamin K antagonists (VKAs, e.g., warfarin) for the majority of patients with VTE, but nuances exist in duration and drug choice.
Initial and Primary Treatment (3 Months)
- NICE: Recommends apixaban or rivaroxaban as first-choice options due to their single-drug approach (no need for initial low molecular weight heparin (LMWH) bridging). Dabigatran and edoxaban are also recommended but require an initial 5-day LMWH course.
- ESC: Similarly favours DOACs but presents all options (apixaban, rivaroxaban, dabigatran, edoxaban) as broadly equivalent, with choice based on patient factors, clinician experience, and cost.
Practical Takeaway: Both guidelines align on DOACs as the standard of care. NICE's preference for apixaban and rivaroxaban is partly driven by NHS cost-effectiveness modelling.
Extended Anticoagulation (Beyond 3 Months)
- NICE: For patients with an unprovoked VTE and a low or moderate risk of bleeding, NICE recommends considering extended anticoagulation. The decision should be based on a discussion of the risks and benefits with the patient.
- ESC: Provides more structured guidance for extended treatment. It recommends extended anticoagulation for most patients with unprovoked VTE who have a low bleeding risk (VTE-BLEED score). For those with a higher bleeding risk, the ESC suggests considering reduced-dose apixaban (2.5 mg twice daily) or rivaroxaban (20 mg once daily) for extended therapy.
Key Difference: The ESC offers a more defined algorithm for extended treatment, including the use of risk scores (VTE-BLEED) and specific reduced-dose DOAC regimens, which are not detailed in the NICE guideline. This provides ESC users with a clearer framework for long-term management.
Special Situations
Cancer-Associated Thrombosis (CAT)
- NICE: Recommends apixaban or rivaroxaban as first-line treatment for CAT, except in patients with gastro-oesophageal or genitourinary cancers at high risk of bleeding, where LMWH (e.g., dalteparin) remains the preferred option.
- ESC: Also recommends DOACs (apixaban, rivaroxaban, edoxaban) for most CAT patients but provides a more extensive list of contraindications for DOACs, including active gastroduodenal ulcers, concomitant strong P-gp/ CYP3A4 inducers, and severe thrombocytopenia.
Practical Takeaway: While both guidelines endorse DOACs for CAT, the ESC's list of contraindications is more exhaustive, potentially leading to more frequent use of LMWH in complex cancer patients.
Renal Impairment
- NICE: Advises using DOACs with caution in patients with a creatinine clearance (CrCl) between 15-29 ml/min and recommends against their use in CrCl <15 ml/min, favouring LMWH or a VKA instead.
- ESC: Provides similar cautions but offers more detailed, drug-specific guidance. For example, it notes that apixaban may be used with caution in severe renal impairment (CrCl 15-29 ml/min) without dose adjustment, while other DOACs are not recommended.
Practical Clinical Flow: Suspected PE
NICE Flow (UK Standard):
- Calculate two-level PE Wells Score.
- PE likely? → Proceed directly to CTPA.
- PE unlikely? → Order a D-dimer.
- D-dimer negative? → PE excluded. D-dimer positive? → Proceed to CTPA.
ESC-Adjusted Flow (for consideration):
- Calculate clinical probability (e.g., Wells Score).
- High probability? → Proceed directly to CTPA.
- Low/Intermediate probability? → Order an age-adjusted D-dimer.
- D-dimer below age-adjusted threshold? → PE excluded. D-dimer positive? → Proceed to CTPA.
Frequently Asked Questions (FAQs)
1. Which guideline should I follow in UK practice?
NICE NG158 represents the official standard for care within the NHS. The ESC guideline provides valuable supplementary evidence and alternative strategies (e.g., age-adjusted D-dimer) that can inform individual clinical judgement, especially where NICE is less specific.
2. What is the single biggest practical difference?
The diagnostic pathway for suspected PE. NICE's binary "likely/unlikely" pathway with standard D-dimer versus the ESC's potential three-level stratification with age-adjusted D-dimer. The latter may reduce unnecessary CTPA scans in elderly patients.
3. Are DOACs safe for all patients with cancer-associated thrombosis?
No. Both guidelines caution against DOAC use in certain cancer populations. The ESC provides a more detailed list of contraindications. For patients with luminal GI cancers at high risk of bleeding, LMWH (e.g., dalteparin) is still the safest choice according to both guidelines.
4. What about extended treatment for unprovoked VTE?
The ESC gives more concrete advice, recommending reduced-dose apixaban or rivaroxaban for extended therapy in selected patients. NICE advises a patient-centred discussion but is less prescriptive on specific regimens. The ESC's approach is a valid evidence-based option.
5. How do the guidelines manage sub-segmental PE?
Both guidelines agree that management should be individualised. For a single sub-segmental PE with no proximal DVT and a low risk of recurrence, clinical surveillance without anticoagulation may be considered if the patient is asymptomatic or has a high bleeding risk.
Source Links
- NICE Guideline NG158 (2025): Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
- ESC Guideline (2024): 2024 ESC Guidelines for the diagnosis and management of acute pulmonary embolism (Published in the European Heart Journal)